Apyx Medical Corporation (NASDAQ:APYX) is a company that specializes in advanced energy solutions for surgical and medical applications. It focuses on developing and commercializing products that improve surgical outcomes. Apyx operates in a competitive landscape with peers like Crinetics Pharmaceuticals, IDEAYA Biosciences, Harrow Health, Evelo Biosciences, and IRadimed Corporation, each with varying financial metrics.
Apyx Medical's ROIC is -26.00%, which is significantly lower than its WACC of 11.53%. This negative ROIC indicates that Apyx is not generating enough returns on its invested capital to cover its cost of capital. The ROIC to WACC ratio of -2.26 further highlights this inefficiency in capital utilization.
In comparison, Crinetics Pharmaceuticals has a ROIC of -34.46% and a WACC of 4.90%, resulting in a ROIC to WACC ratio of -7.04. Similarly, IDEAYA Biosciences shows a ROIC of -38.96% against a WACC of 4.52%, leading to a ratio of -8.61. Both companies, like Apyx, struggle to generate returns above their cost of capital.
Harrow Health presents a slightly better scenario with a ROIC of 4.90% and a WACC of 5.87%, resulting in a ROIC to WACC ratio of 0.83. Although positive, it still indicates that Harrow Health's returns are just below its cost of capital. On the other hand, Evelo Biosciences has a significantly negative ROIC of -201.37% compared to its WACC of 9.04%, with a ratio of -22.28, showing severe inefficiency.
IRadimed Corporation stands out with a ROIC of 19.35% and a WACC of 8.44%, resulting in a ROIC to WACC ratio of 2.29. This indicates that IRadimed is effectively generating returns well above its cost of capital, making it the most efficient among the peers in terms of capital utilization.
